ReviewNature reviews. Nephrology2017
Metabolomics for clinical use and research in chronic kidney disease.
Review in Nature reviews. Nephrology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05719714 (Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease), which is not on this map. Cited by 173 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease
Who cites it
173 citing papers in PubMed, 325 citations in OpenAlex.
- Trial
- A nomogram based on metabolic profiling to discriminate lung cancer among patients with lung nodules.The Journal of international medical research · 2023Trial
- Plasma metabolites and lipids associate with kidney function and kidney volume in hypertensive ADPKD patients early in the disease course.BMC nephrology · 2019Trial
- Effects of linagliptin on endothelial function and postprandial lipids in coronary artery disease patients with early diabetes: a randomized, placebo-controlled, double-blind trial.Cardiovascular diabetology · 2018Trial
- 1,5-Anhydroglucitol predicts CKD progression in macroalbuminuric diabetic kidney disease: results from non-targeted metabolomics.Metabolomics : Official journal of the Metabolomic Society · 2018Trial
- Integrative transcriptomic and single-cell analysis identifies anoikis-related molecular signatures in vascular calcification.Renal failure · 2026Article
- HILIC-MS/MS-based strategy for quantitative amino acid profiling in multiple biological matrices and its application in kidney disease samples.Analytical and bioanalytical chemistry · 2026Article
- NMR Metabolomics in Veterinary Medicine: From Biomarker Discovery to Clinical Implementation.Veterinary sciences · 2026Review
- Metabolomic profiling in IgA nephropathy: urinary and salivary biomarker insights.BMC nephrology · 2026Article
- Multi-Modal, Machine Learning-Driven Framework Integrating Multi-Omics for Personalized Chronic Kidney Disease Management.Journal of clinical medicine · 2026Review
- Systematic Evaluation of Plasma and Urine Metabolites to Predict the Risk of Adverse Kidney-related Outcomes in Chronic Kidney Disease: The GCKD Study∗.Kidney medicine · 2026Article
- Kidney Transplantation and the Gut-Kidney Axis: Microbial, Metabolic, and Nutritional Implications for Graft and Patient Outcomes.Nutrients · 2026Review
- From Parallel Programming to Bidirectional Crosstalk: The Brain-Kidney Axis in Cardiovascular-Kidney-Metabolic Syndrome.Antioxidants (Basel, Switzerland) · 2026Review
- Evaluation of equation as a classifier for kidney function in domestic cats: a proof-of-concept study.npj aging · 2026Article
- Acylcarnitines and prediction of renal function decline in type 2 diabetes.BMJ open diabetes research & care · 2026Article
- Podocyte Markers as Diagnostic Biomarkers of Diabetic Nephropathy: A Case-Control Comparison to Haemato-Biochemical Markers in a Ghanaian Population.Endocrinology, diabetes & metabolism · 2026Observational
- Serum metabolomics identifies gut-derived uremic toxins and bile acid dysregulation associated with chronic kidney disease severity.Scientific reports · 2026Article
- Spatial metabolomics: A new tool for unravelling the metabolic disorders and heterogeneity in diabetic kidney disease (Review).International journal of molecular medicine · 2026Review
- Urinary Metabolomics Predict Acute Kidney Injury in Very-Low-Birth-Weight Infants with Patent Ductus Arteriosus.Biomolecules · 2026Article
- Article
113 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic kidney disease (CKD) has a high prevalence in the general population and is associated with high mortality; a need therefore exists for better biomarkers for diagnosis, monitoring of disease progression and therapy stratification. Moreover, very sensitive biomarkers are needed in drug development and clinical research to increase understanding of the efficacy and safety of potential and existing therapies. Metabolomics analyses can identify and quantify all metabolites present in a given sample, covering hundreds to thousands of metabolites. Sample preparation for metabolomics requires a very fast arrest of biochemical processes. Present key technologies for metabolomics are mass spectrometry and proton nuclear magnetic resonance spectroscopy, which require sophisticated biostatistic and bioinformatic data analyses. The use of metabolomics has been instrumental in identifying new biomarkers of CKD such as acylcarnitines, glycerolipids, dimethylarginines and metabolites of tryptophan, the citric acid cycle and the urea cycle. Biomarkers such as c-mannosyl tryptophan and pseudouridine have better performance in CKD stratification than does creatinine. Future challenges in metabolomics analyses are prospective studies and deconvolution of CKD biomarkers from those of other diseases such as metabolic syndrome, diabetes mellitus, inflammatory conditions, stress and cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.